Please use this identifier to cite or link to this item:
|Title:||Programmed cell death-1 inhibition in lymphoma.|
|Authors:||Hawkes, Eliza A.|
|Place of publication:||Philadelphia, PA|
|Publication Title:||The Lancet Oncology|
|Abstract:||Cancers can evade the host immune system by inducing upregulation of immune inhibitory signals. Anti-programmed cell death-1 (PD-1) monoclonal antibodies block these inhibitory signals allowing the host to mount an immune response against malignant cells. This class of drugs is active in solid tumours, where upregulation of cell-surface PD-1 ligand proteins is nearly uniform. Because lymphoma is a malignancy of immune system cells, the role of the PD-1 pathway in these neoplasms is more complex. However, early clinical trials using PD-1 inhibitors have shown significant clinical activity in various subtypes of relapsed lymphoma. In this Review, we assess the scientific literature on the role of the PD-1 pathway in lymphoma, the relevant clinical data for PD-1 inhibition, and future strategies for this next generation of anticancer agents.|
|Internal ID Number:||00777|
|Health Subject:||CELL DEATH|
PROGRAMMED CELL DEATH 1 RECEPTOR
|Appears in Collections:||Research Output|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.